Tumors escape immunosurveillance by overexpressing the proteasome activator PSME3

References

• Joffre OP, Segura E, Savina A, Amigorena S. Cross-presentation by dendritic cells. Nat Rev Immunol. 2012;12:557–16.
   PubMed Web of Science ®Google Scholar
• Yewdell JW, Anton LC, Bennink JR. Defective ribosomal products (DRiPs): a major source of antigenic peptides for MHC class I molecules? J Immunol. 1996;157:1823–1826.
   PubMed Web of Science ®Google Scholar
• Coulie PG, Lehmann F, Lethe B, Herman J, Lurquin C, Andrawiss M, Boon T. A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma. Proc Natl Acad Sci U S A. 1995;92:7976–7980. doi:10.1073/pnas.92.17.7976.
   PubMed Web of Science ®Google Scholar
• Guilloux Y, Lucas S, Brichard VG, Van Pel A, Viret C, De Plaen E, Brasseur F, Lethé B, Jotereau F, Boon T, et al. A peptide recognized by human cytolytic T lymphocytes on HLA-A2 melanomas is encoded by an intron sequence of the N-acetylglucosaminyltransferase V gene. J Exp Med. 1996;183:1173–1183. doi:10.1084/jem.183.3.1173.
   PubMed Web of Science ®Google Scholar
• Shastri N, Cardinaud S, Schwab SR, Serwold T, Kunisawa J. All the peptides that fit: the beginning, the middle, and the end of the MHC class I antigen-processing pathway. Immunol Rev. 2005;207:31–41. doi:10.1111/j.0105-2896.2005.00321.x.
   PubMed Web of Science ®Google Scholar
• Apcher S, Daskalogianni C, Lejeune F, Manoury B, Imhoos G, Heslop L, Fahraeus R. Major source of antigenic peptides for the MHC class I pathway is produced during the pioneer round of mRNA translation. Proc Natl Acad Sci U S A. 2011;108:11572–11577. doi:10.1073/pnas.1104104108.
   PubMed Web of Science ®Google Scholar
• Apcher S, Millot G, Daskalogianni C, Scherl A, Manoury B, Fahraeus R. Translation of pre-spliced RNAs in the nuclear compartment generates peptides for the MHC class I pathway. Proc Natl Acad Sci U S A. 2013;110:17951–17956. doi:10.1073/pnas.1309956110.
   PubMed Web of Science ®Google Scholar
• Duvallet E, Boulpicante M, Yamazaki T, Daskalogianni C, Prado Martins R, Baconnais S, Manoury B, Fahraeus R, Apcher S. Exosome-driven transfer of tumor-associated Pioneer Translation Products (TA-PTPs) for the MHC class I cross-presentation pathway. Oncoimmunology. 2016;5(9):e1198865. doi:10.1080/2162402X.2016.1198865.
   PubMed Web of Science ®Google Scholar
• Collins GA, Goldberg AL. The Logic of the 26S Proteasome. Cell. 2017;169:792–806. doi:10.1016/j.cell.2017.04.023.
   PubMed Web of Science ®Google Scholar
• Kish-Trier E, Hill CP. Structural biology of the proteasome. Annu Rev Biophys. 2013;42:29–49. doi:10.1146/annurev-biophys-083012-130417.
   PubMed Web of Science ®Google Scholar
• Leone P, Shin EC, Perosa F, Vacca A, Dammacco F, Racanelli V. MHC class I antigen processing and presenting machinery: organization, function, and defects in tumor cells. J Natl Cancer Inst. 2013;105:1172–1187. doi:10.1093/jnci/djt184.
   PubMed Web of Science ®Google Scholar
• Whitby FG, Masters EI, Kramer L, Knowlton JR, Yao Y, Wang CC, Hill CP. Structural basis for the activation of 20S proteasomes by 11S regulators. Nature. 2000;408:115–120. doi:10.1038/35040607.
   PubMed Web of Science ®Google Scholar
• Cascio P, Call M, Petre BM, Walz T, Goldberg AL. Properties of the hybrid form of the 26S proteasome containing both 19S and PA28 complexes. Embo J. 2002;21:2636–2645. doi:10.1093/emboj/21.11.2636.
   PubMed Web of Science ®Google Scholar
• Cascio P. PA28alphabeta: the enigmatic magic ring of the proteasome? Biomolecules. 2014;4:566–584. doi:10.3390/biom4020566.
   PubMedGoogle Scholar
• Soza A, Knuehl C, Groettrup M, Henklein P, Tanaka K, Kloetzel PM. Expression and subcellular localization of mouse 20S proteasome activator complex PA28. FEBS Lett. 1997;413:27–34. doi:10.1016/S0014-5793(97)00864-8.
   PubMed Web of Science ®Google Scholar
• Wojcik C, Tanaka K, Paweletz N, Naab U, Wilk S. Proteasome activator (PA28) subunits, alpha, beta and gamma (Ki antigen) in NT2 neuronal precursor cells and HeLa S3 cells. Eur J Cell Biol. 1998;77:151–160. doi:10.1016/S0171-9335(98)80083-6.
   PubMed Web of Science ®Google Scholar
• Chen X, Barton LF, Chi Y, Clurman BE, Roberts JM. Ubiquitin-independent degradation of cell-cycle inhibitors by the REGgamma proteasome. Mol Cell. 2007;26:843–852. doi:10.1016/j.molcel.2007.05.022.
   PubMed Web of Science ®Google Scholar
• Li X, Amazit L, Long W, Lonard DM, Monaco JJ, O’Malley BW. Ubiquitin- and ATP-independent proteolytic turnover of p21 by the REGgamma-proteasome pathway. Mol Cell. 2007;26:831–842. doi:10.1016/j.molcel.2007.05.028.
   PubMed Web of Science ®Google Scholar
• Li X, Lonard DM, Jung SY, Malovannaya A, Feng Q, Qin J, Tsai SY, Tsai M-J, O’Malley BW. The SRC-3/AIB1 coactivator is degraded in a ubiquitin- and ATP-independent manner by the REGgamma proteasome. Cell. 2006;124:381–392. doi:10.1016/j.cell.2005.11.037.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Zhang R. Proteasome activator PA28 gamma regulates p53 by enhancing its MDM2-mediated degradation. Embo J. 2008;27:852–864. doi:10.1038/emboj.2008.25.
   PubMed Web of Science ®Google Scholar
• Chai F, Liang Y, Bi J, Chen L, Zhang F, Cui Y, Bian X, Jiang J. High expression of REGy is associated with metastasis and poor prognosis of patients with breast cancer. Int J Clin Exp Pathol. 2014:7834–43 p.
   Google Scholar
• Baldin V, Militello M, Thomas Y, Doucet C, Fic W, Boireau S, Jariel-Encontre I, Piechaczyk M, Bertrand E, Tazi J, et al. A novel role for PA28gamma-proteasome in nuclear speckle organization and SR protein trafficking. Mol Biol Cell. 2008;19:1706–1716. doi:10.1091/mbc.e07-07-0637.
   PubMed Web of Science ®Google Scholar
• Cioce M, Boulon S, Matera AG, Lamond AI. UV-induced fragmentation of Cajal bodies. J Cell Biol. 2006;175:401–413. doi:10.1083/jcb.200604099.
   PubMed Web of Science ®Google Scholar
• Zannini L, Buscemi G, Fontanella E, Lisanti S, Delia D. REGgamma/PA28gamma proteasome activator interacts with PML and Chk2 and affects PML nuclear bodies number. Cell Cycle. 2009;8:2399–2407. doi:10.4161/cc.8.15.9084.
   PubMed Web of Science ®Google Scholar
• Fort P, Kajava AV, Delsuc F, Coux O. Evolution of proteasome regulators in eukaryotes. Genome Biol Evol. 2015;7:1363–1379. doi:10.1093/gbe/evv068.
   PubMed Web of Science ®Google Scholar
• Boulon S, Westman BJ, Hutten S, Boisvert FM, Lamond AI. The nucleolus under stress. Mol Cell. 2010;40:216–227. doi:10.1016/j.molcel.2010.09.024.
   PubMed Web of Science ®Google Scholar
• Welk V, Coux O, Kleene V, Abeza C, Trumbach D, Eickelberg O, Meiners S. Inhibition of Proteasome Activity Induces Formation of Alternative Proteasome Complexes. J Biol Chem. 2016;291:13147–13159. doi:10.1074/jbc.M116.717652.
   PubMed Web of Science ®Google Scholar
• Jonik-Nowak B, Menneteau T, Fesquet D, Baldin V, Bonne-Andrea C, Mechali F, Fabre B, Boisguerin P, de Rossi S, Henriquet C, et al. PIP30/FAM192A is a novel regulator of the nuclear proteasome activator PA28gamma. Proc Natl Acad Sci U S A. 2018;115:E6477–E86. doi:10.1073/pnas.1722299115.
   PubMed Web of Science ®Google Scholar
• Groettrup M, Kirk CJ, Basler M. Proteasomes in immune cells: more than peptide producers? Nat Rev Immunol. 2010;10:73–78. doi:10.1038/nri2687.
   PubMed Web of Science ®Google Scholar
• Barton LF, Runnels HA, Schell TD, Cho Y, Gibbons R, Tevethia SS, Deepe GS, Monaco JJ. Immune defects in 28-kDa proteasome activator gamma-deficient mice. J Immunol. 2004;172:3948–3954. doi:10.4049/jimmunol.172.6.3948.
   PubMed Web of Science ®Google Scholar
• Murata S, Kawahara H, Tohma S, Yamamoto K, Kasahara M, Nabeshima Y, Tanaka K, Chiba T. Growth retardation in mice lacking the proteasome activator PA28gamma. J Biol Chem. 1999;274:38211–38215. doi:10.1074/jbc.274.53.38211.
   PubMed Web of Science ®Google Scholar
• Shastri N, Gonzalez F. Endogenous generation and presentation of the ovalbumin peptide/Kb complex to T cells. J Immunol. 1993;150:2724–2736.
   PubMed Web of Science ®Google Scholar
• Perchellet A, Stromnes I, Pang JM, Goverman J. CD8+ T cells maintain tolerance to myelin basic protein by ‘epitope theft’. Nat Immunol. 2004;5:606–614. doi:10.1038/ni1073.
   PubMed Web of Science ®Google Scholar
• Cafri G, Sharbi-Yunger A, Tzehoval E, Eisenbach L. Production of LacZ inducible T cell hybridoma specific for human and mouse gp100(2)(5)(-)(3)(3) peptides. PLoS One. 2013;8:e55583. doi:10.1371/journal.pone.0055583.
   PubMed Web of Science ®Google Scholar
• Cascio P, Goldberg AL. Preparation of hybrid (19S-20S-PA28) proteasome complexes and analysis of peptides generated during protein degradation. Methods Enzymol. 2005;398:336–352.
   PubMed Web of Science ®Google Scholar
• Raule M, Cerruti F, Benaroudj N, Migotti R, Kikuchi J, Bachi A, Navon A, Dittmar G, Cascio P. PA28alphabeta reduces size and increases hydrophilicity of 20S immunoproteasome peptide products. Chem Biol. 2014;21:470–480. doi:10.1016/j.chembiol.2014.02.006.
   PubMedGoogle Scholar
• Raule M, Cerruti F, Cascio P. Enhanced rate of degradation of basic proteins by 26S immunoproteasomes. Biochim Biophys Acta. 2014;1843:1942–1947. doi:10.1016/j.bbamcr.2014.05.005.
   PubMed Web of Science ®Google Scholar
• Rappsilber J, Ishihama Y, Mann M. Stop and go extraction tips for matrix-assisted laser desorption/ionization, nanoelectrospray, and LC/MS sample pretreatment in proteomics. Anal Chem. 2003;75:663–670. doi:10.1021/ac026117i.
   PubMed Web of Science ®Google Scholar
• Rappsilber J, Mann M, Ishihama Y. Protocol for micro-purification, enrichment, pre-fractionation and storage of peptides for proteomics using StageTips. Nat Protoc. 2007;2:1896–1906. doi:10.1038/nprot.2007.261.
   PubMed Web of Science ®Google Scholar
• Wang X, Tu S, Tan J, Tian T, Ran L, Rodier JF, Ren G. REG gamma: a potential marker in breast cancer and effect on cell cycle and proliferation of breast cancer cell. Med Oncol. 2011;28:31–41. doi:10.1007/s12032-010-9546-8.
   PubMed Web of Science ®Google Scholar
• Chai F, Liang Y, Bi J, Chen L, Zhang F, Cui Y, Bian X, Jiang J. High expression of REGgamma is associated with metastasis and poor prognosis of patients with breast cancer. Int J Clin Exp Pathol. 2014;7:7834–7843.
   PubMedGoogle Scholar
• He J, Cui L, Zeng Y, Wang G, Zhou P, Yang Y, Ji L, Zhao Y, Chen J, Wang Z, et al. REGgamma is associated with multiple oncogenic pathways in human cancers. BMC Cancer. 2012;12:75. doi:10.1186/1471-2407-12-75.
   PubMed Web of Science ®Google Scholar
• Yu G, Zhao Y, He J, Lonard DM, Mao CA, Wang G, Li M, Li X. Comparative analysis of REG{gamma} expression in mouse and human tissues. J Mol Cell Biol. 2010;2:192–198. doi:10.1093/jmcb/mjq009.
   PubMed Web of Science ®Google Scholar
• Craiu A, Akopian T, Goldberg A, Rock KL. Two distinct proteolytic processes in the generation of a major histocompatibility complex class I-presented peptide. Proc Natl Acad Sci U S A. 1997;94:10850–10855. doi:10.1073/pnas.94.20.10850.
   PubMed Web of Science ®Google Scholar
• Sijts EJ, Kloetzel PM. The role of the proteasome in the generation of MHC class I ligands and immune responses. Cell Mol Life Sci. 2011;68:1491–1502. doi:10.1007/s00018-011-0657-y.
   PubMed Web of Science ®Google Scholar
• Kisselev AF, Goldberg AL. Proteasome inhibitors: from research tools to drug candidates. Chem Biol. 2001;8:739–758. doi:10.1016/S1074-5521(01)00056-4.
   PubMed Web of Science ®Google Scholar
• Schwarz K, de Giuli R, Schmidtke G, Kostka S, van den Broek M, Kim KB, Crews CM, Kraft R, Groettrup M. The selective proteasome inhibitors lactacystin and epoxomicin can be used to either up- or down-regulate antigen presentation at nontoxic doses. J Immunol. 2000;164:6147–6157. doi:10.4049/jimmunol.164.12.6147.
   PubMed Web of Science ®Google Scholar
• Giles KM, Brown RA, Ganda C, Podgorny MJ, Candy PA, Wintle LC, Richardson KL, Kalinowski FC, Stuart LM, Epis MR, et al. microRNA-7-5p inhibits melanoma cell proliferation and metastasis by suppressing RelA/NF-κB. Oncotarget. 2016;7:31663–31680. doi:10.18632/oncotarget.9421.
   PubMedGoogle Scholar
• Xiong S, Zheng Y, Jiang P, Liu R, Liu X, Chu Y. MicroRNA-7 inhibits the growth of human non-small cell lung cancer A549 cells through targeting BCL-2. Int J Biol Sci. 2011;7:805–814. doi:10.7150/ijbs.7.805.
   PubMed Web of Science ®Google Scholar
• Kefas B, Godlewski J, Comeau L, Li Y, Abounader R, Hawkinson M, Lee J, Fine H, Chiocca EA, Lawler S, et al. microRNA-7 inhibits the epidermal growth factor receptor and the Akt pathway and is down-regulated in glioblastoma. Cancer Res. 2008;68:3566–3572. doi:10.1158/0008-5472.CAN-07-6639.
   PubMed Web of Science ®Google Scholar
• Saydam O, Senol O, Wurdinger T, Mizrak A, Ozdener GB, Stemmer-Rachamimov AO, Yi M, Stephens RM, Krichevsky AM, Saydam N, et al. miRNA-7 attenuation in Schwannoma tumors stimulates growth by upregulating three oncogenic signaling pathways. Cancer Res. 2011;71(3):852–861. doi:10.1158/0008-5472.CAN-10-1219.
   PubMed Web of Science ®Google Scholar
• Xiong S, Zheng Y, Jiang P, Liu R, Liu X, Qian J, Gu J, Chang L, Ge D, Chu Y, et al. PA28gamma emerges as a novel functional target of tumour suppressor microRNA-7 in non-small-cell lung cancer. Br J Cancer. 2014;110(2):353–362. doi:10.1038/bjc.2013.728.
   PubMed Web of Science ®Google Scholar
• Ali A, Wang Z, Fu J, Ji L, Liu J, Li L, Wang H, Chen J, Caulin C, Myers JN, et al. Differential regulation of the REGgamma-proteasome pathway by p53/TGF-beta signalling and mutant p53 in cancer cells. Nat Commun. 2013;4:2667. doi:10.1038/ncomms3667.
   PubMed Web of Science ®Google Scholar
• Kanai K, Aramata S, Katakami S, Yasuda K, Kataoka K. Proteasome activator PA28gamma stimulates degradation of GSK3-phosphorylated insulin transcription activator MAFA. J Mol Endocrinol. 2011;47:119–127. doi:10.1530/JME-11-0044.
   Web of Science ®Google Scholar
• Groll M, Bajorek M, Kohler A, Moroder L, Rubin DM, Huber R, Rubin DM, Huber R. A gated channel into the proteasome core particle. Nat Struct Biol. 2000;7:1062–1067. doi:10.1038/80992.
   PubMedGoogle Scholar
• Coux O, Tanaka K, Goldberg AL. Structure and functions of the 20S and 26S proteasomes. Annu Rev Biochem. 1996;65:801–847. doi:10.1146/annurev.bi.65.070196.004101.
   PubMed Web of Science ®Google Scholar
• Osmulski PA, Hochstrasser M, Gaczynska M. A tetrahedral transition state at the active sites of the 20S proteasome is coupled to opening of the alpha-ring channel. Structure. 2009;17:1137–1147. doi:10.1016/j.str.2009.06.011.
   PubMed Web of Science ®Google Scholar
• Osmulski PA, Gaczynska M. Nanoenzymology of the 20S proteasome: proteasomal actions are controlled by the allosteric transition. Biochemistry. 2002;41:7047–7053. doi:10.1021/bi0159130.
   PubMed Web of Science ®Google Scholar
• Baugh JM, Pilipenko EV. 20S proteasome differentially alters translation of different mRNAs via the cleavage of eIF4F and eIF3. Mol Cell. 2004;16:575–586. doi:10.1016/j.molcel.2004.10.017.
   PubMed Web of Science ®Google Scholar
• Orlowski M, Wilk S. Ubiquitin-independent proteolytic functions of the proteasome. Arch Biochem Biophys. 2003;415:1–5. doi:10.1016/S0003-9861(03)00197-8.
   PubMed Web of Science ®Google Scholar
• Davies KJ. Degradation of oxidized proteins by the 20S proteasome. Biochimie. 2001;83:301–310. doi:10.1016/S0300-9084(01)01250-0.
   PubMed Web of Science ®Google Scholar
• Kisselev AF, Akopian TN, Woo KM, Goldberg AL. The sizes of peptides generated from protein by mammalian 26 and 20 S proteasomes. Implications for understanding the degradative mechanism and antigen presentation. J Biol Chem. 1999;274:3363–3371. doi:10.1074/jbc.274.6.3363.
   PubMed Web of Science ®Google Scholar
• Nussbaum AK, Dick TP, Keilholz W, Schirle M, Stevanovic S, Dietz K, Heinemeyer W, Groll M, Wolf DH, Huber R, et al. Cleavage motifs of the yeast 20S proteasome beta subunits deduced from digests of enolase 1. Proc Natl Acad Sci U S A. 1998;95:12504–12509. doi:10.1073/pnas.95.21.12504.
   PubMed Web of Science ®Google Scholar
• Seliger B. Molecular mechanisms of MHC class I abnormalities and APM components in human tumors. Cancer Immunol, Immunother. 2008;57:1719–1726. doi:10.1007/s00262-008-0515-4.
   PubMed Web of Science ®Google Scholar
• Cerruti F, Martano M, Petterino C, Bollo E, Morello E, Bruno R, Buracco P, Cascio P. Enhanced expression of interferon-gamma-induced antigen-processing machinery components in a spontaneously occurring cancer. Neoplasia. 2007;9:960–969. doi:10.1593/neo.07649.
   PubMed Web of Science ®Google Scholar
• Lafarga M, Berciano MT, Pena E, Mayo I, Castano JG, Bohmann D, Rodrigues JP, Tavanez JP, Carmo-Fonseca M. Clastosome: a subtype of nuclear body enriched in 19S and 20S proteasomes, ubiquitin, and protein substrates of proteasome. Mol Biol Cell. 2002;13:2771–2782. doi:10.1091/mbc.e02-03-0122.
   PubMed Web of Science ®Google Scholar
• Guillaume B, Chapiro J, Stroobant V, Colau D, Van Holle B, Parvizi G, Bousquet-Dubouch M-P, Theate I, Parmentier N, Van den Eynde BJ, et al. Two abundant proteasome subtypes that uniquely process some antigens presented by HLA class I molecules. Proc Natl Acad Sci U S A. 2010;107:18599–18604. doi:10.1073/pnas.1009778107.
   PubMed Web of Science ®Google Scholar
• Morel S, Levy F, Burlet-Schiltz O, Brasseur F, Probst-Kepper M, Peitrequin A-L, Monsarrat B, Van Velthoven R, Cerottini J-C, Boon T, et al. Processing of some antigens by the standard proteasome but not by the immunoproteasome results in poor presentation by dendritic cells. Immunity. 2000;12(1):107–117. doi:10.1016/S1074-7613(00)80163-6.
   PubMed Web of Science ®Google Scholar
• Van den Eynde BJ, Morel S. Differential processing of class-I-restricted epitopes by the standard proteasome and the immunoproteasome. Curr Opin Immunol. 2001;13:147–153. doi:10.1016/S0952-7915(00)00197-7.
   PubMed Web of Science ®Google Scholar
• Vigneron N, Van den Eynde BJ. Proteasome subtypes and the processing of tumor antigens: increasing antigenic diversity. Curr Opin Immunol. 2012;24:84–91. doi:10.1016/j.coi.2011.12.002.
   PubMed Web of Science ®Google Scholar
• Cascio P, Hilton C, Kisselev AF, Rock KL, Goldberg AL. 26S proteasomes and immunoproteasomes produce mainly N-extended versions of an antigenic peptide. Embo J. 2001;20:2357–2366. doi:10.1093/emboj/20.10.2357.
   PubMed Web of Science ®Google Scholar
• Smart AC, Margolis CA, Pimentel H, He MX, Miao D, Adeegbe D, Fugmann T, Wong -K-K, Van Allen EM. Intron retention is a source of neoepitopes in cancer. Nat Biotechnol. 2018;36:1056–1058. doi:10.1038/nbt.4239.
   PubMed Web of Science ®Google Scholar